Moody Aldrich Partners LLC Cuts Stock Holdings in Axsome Therapeutics, Inc. $AXSM

01 Jan 2026, 08:08 by Renee Jackson · The Cerbat Gem

Moody Aldrich Partners LLC reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 16.2% during the third quarter, Holdings Channel reports. The institutional investor owned 51,476 shares of the company’s stock after selling 9,934 shares during the quarter. Axsome Therapeutics comprises 1.2% of Moody Aldrich Partners LLC’s portfolio, making the stock its 16th biggest holding. Moody Aldrich Partners LLC’s holdings in Axsome Therapeutics were worth $6,252,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank purchased a new stake in Axsome Therapeutics during the 2nd quarter valued at about $48,889,000. Adage Capital Partners GP L.L.C. increased its stake in Axsome Therapeutics by 831.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock worth $46,662,000 after purchasing an additional 399,000 shares during the period. Hood River Capital Management LLC bought a new stake in Axsome Therapeutics in the second quarter valued at approximately $38,740,000. BVF Inc. IL boosted its stake in shares of Axsome Therapeutics by 21.8% during the first quarter. BVF Inc. IL now owns 1,690,221 shares of the company’s stock valued at $197,130,000 after purchasing an additional 302,157 shares during the period. Finally, Bank of America Corp DE grew its holdings in shares of Axsome Therapeutics by 41.1% in the second quarter. Bank of America Corp DE now owns 753,429 shares of the company’s stock worth $78,650,000 after purchasing an additional 219,527 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Up 22.8%

Shares of NASDAQ AXSM opened at $182.64 on Thursday. The firm has a fifty day simple moving average of $145.19 and a two-hundred day simple moving average of $124.51. Axsome Therapeutics, Inc. has a 12 month low of $79.19 and a 12 month high of $184.40. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The firm has a market capitalization of $9.21 billion, a PE ratio of -39.11 and a beta of 0.48.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company had revenue of $170.99 million for the quarter, compared to the consensus estimate of $162.96 million. The firm’s revenue for the quarter was up 63.2% on a year-over-year basis. Equities analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insiders Place Their Bets

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 10,558 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $148.18, for a total transaction of $1,564,484.44. Following the transaction, the chief executive officer owned 7,229 shares in the company, valued at approximately $1,071,193.22. This represents a 59.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 289,296 shares of company stock worth $38,882,311. Insiders own 22.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. HC Wainwright lifted their target price on shares of Axsome Therapeutics from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Royal Bank Of Canada raised their price target on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Morgan Stanley restated an “overweight” rating on shares of Axsome Therapeutics in a research report on Wednesday. Needham & Company LLC increased their target price on shares of Axsome Therapeutics from $154.00 to $169.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Mizuho set a $217.00 target price on Axsome Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $183.94.

Get Our Latest Stock Report on Axsome Therapeutics

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

Positive Sentiment: FDA granted priority review to AXS‑05 (Auvelity) for agitation in Alzheimer’s disease — a faster review path increases the chance of an earlier approval and near‑term commercial opportunity, which is the main catalyst cited for the stock’s strong jump. Read More.
Positive Sentiment: Company announced FDA acceptance and priority review of a supplemental NDA for Auvelity (AXS‑05), confirming the agency’s formal review and prompting coverage across news services. Read More.
Positive Sentiment: FDA provided formal pre‑NDA meeting minutes for AXS‑12 (reboxetine) in narcolepsy, keeping an NDA submission on schedule for January 2026 — another potential product that could expand Axsome’s CNS franchise. Read More.
Neutral Sentiment: Analyst activity: Needham raised its price target to $169 and maintained a Buy rating, which signals analyst support even though the target sits below the intraday stock level — mixed signal on near‑term valuation. Read More.
Neutral Sentiment: Several outlets and analyst summaries explain the stock move (coverage includes IBD, Schaeffer’s, AAII) — media amplification can extend buying momentum but does not change fundamentals by itself. Read More.

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.